Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, GSK Plc ADR’s stock clocked out at $47.27, down -2.48% from its previous closing price of $48.47. In other words, the price has decreased by -$2.48 from its previous closing price. On the day, 3.78 million shares were traded. GSK stock price reached its highest trading level at $48.2901 during the session, while it also had its lowest trading level at $47.2.
Ratios:
To gain a deeper understanding of GSK’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 21.44 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.92. For the most recent quarter (mrq), Quick Ratio is recorded 0.55 and its Current Ratio is at 0.84. In the meantime, Its Debt-to-Equity ratio is 1.10 whereas as Long-Term Debt/Eq ratio is at 0.92.
On April 15, 2025, Exane BNP Paribas started tracking the stock assigning a Neutral rating and target price of $35.25.Exane BNP Paribas initiated its Neutral rating on April 15, 2025, with a $35.25 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GSK now has a Market Capitalization of 95754092544 and an Enterprise Value of 209188225024. As of this moment, GSK’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.48, and their Forward P/E ratio for the next fiscal year is 9.72. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.01. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.27 while its Price-to-Book (P/B) ratio in mrq is 4.38. Its current Enterprise Value per Revenue stands at 6.503 whereas that against EBITDA is 21.976.
Stock Price History:
The Beta on a monthly basis for GSK is 0.47, which has changed by 0.40696657 over the last 52 weeks, in comparison to a change of 0.12529528 over the same period for the S&P500. Over the past 52 weeks, GSK has reached a high of $49.31, while it has fallen to a 52-week low of $31.72. The 50-Day Moving Average of the stock is 2.96%, while the 200-Day Moving Average is calculated to be 16.80%.
Shares Statistics:
It appears that GSK traded 5.25M shares on average per day over the past three months and 4130230 shares per day over the past ten days. A total of 2.02B shares are outstanding, with a floating share count of 2.02B. Insiders hold about 0.00% of the company’s shares, while institutions hold 19.27% stake in the company. Shares short for GSK as of 1763078400 were 12554953 with a Short Ratio of 2.39, compared to 1760486400 on 13334110. Therefore, it implies a Short% of Shares Outstanding of 12554953 and a Short% of Float of 0.63.
Dividends & Splits
With its trailing 12-month dividend rate of 0.64, GSK has a forward annual dividend rate of 1.69. Against a Trailing Annual Dividend Yield of 0.013204043. The stock’s 5-year Average Dividend Yield is 4.63. The current Payout Ratio is 94.89% for GSK, which recently paid a dividend on 2025-11-14 with an ex-dividend date of 2025-11-14. Stock splits for the company last occurred on 2022-07-22 when the company split stock in a 1226:1000 ratio.
Earnings Estimates
A comprehensive evaluation of GSK Plc ADR (GSK) is underway, with the input of 2.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $1.2, with high estimates of $1.2 and low estimates of $1.2.
Analysts are recommending an EPS of between $4.49 and $3.76 for the fiscal current year, implying an average EPS of $4.27. EPS for the following year is $4.65, with 4.0 analysts recommending between $5.05 and $4.24.
Revenue Estimates
In. The current quarter, 7 analysts expect revenue to total $8.42B. It ranges from a high estimate of $8.62B to a low estimate of $8.18B. As of. The current estimate, GSK Plc ADR’s year-ago sales were $8.12BFor the next quarter, 7 analysts are estimating revenue of $7.81B. There is a high estimate of $7.81B for the next quarter, whereas the lowest estimate is $7.81B.
A total of 18 analysts have provided revenue estimates for GSK’s current fiscal year. The highest revenue estimate was $32.84B, while the lowest revenue estimate was $32.09B, resulting in an average revenue estimate of $32.5B. In the same quarter a year ago, actual revenue was $31.38BBased on 15 analysts’ estimates, the company’s revenue will be $34.27B in the next fiscal year. The high estimate is $35.67B and the low estimate is $33.43B.
